# Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.

> **NCT02273167** · PHASE3 · COMPLETED · sponsor: **Norgine** · enrollment: 849 (actual)

## Conditions studied

- Colorectal Cancer
- Colorectal Carcinoma
- Colon Cleansing

## Interventions

- **DRUG:** NER1006, 2-Day Split-Dosing
- **DRUG:** NER1006,1-Day Morning Split-Dosing
- **DRUG:** MOVIPREP, 2-Day Split-Dosing

## Key facts

- **NCT ID:** NCT02273167
- **Lead sponsor:** Norgine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 849 (ACTUAL)
- **Last updated:** 2018-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02273167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02273167, "Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02273167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*